Drug intelligence / Profile preview

CB-839 + erlotinib

Development stage: Unknown
Lead developer: Calithera Biosciences, Inc
Modality: Small Molecules
Administration: Oral

Overview

CB-Erl is a combination therapy consisting of the glutaminase inhibitor CB-839 and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib. This combination is being investigated for use in patients with advanced non-small cell lung cancer (NSCLC) lacking the T790M EGFR mutation. CB-839 inhibits glutaminase, an enzyme critical for tumor cell metabolism and survival, while erlotinib targets EGFR signaling pathways involved in tumor growth and proliferation. The rationale behind this combination is to exploit metabolic vulnerabilities in cancer cells alongside targeted inhibition of oncogenic signaling[1][2][6][8].

Other names: CB-Erl

Targets

GLS1 (Glutaminase 1)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on CB-839 + erlotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB-839 + erlotinib.

Explore the full profile